Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings.

As part of the agreement, Merck will leverage Tempus AI, Inc. (NASDAQ:TEM)’s de-identified data and Lens Platform and Workspaces technologies to generate new discoveries and accelerate the development and effective use of candidate therapies on a large scale.

In other news, on February 25, JPMorgan analyst Casey Woodring slashed the stock’s price target to $60 from $80, with a Neutral rating, following the company’s Q4 earnings call a day prior.

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Photo from Iovance Biotherapeutics website

According to TipRanks, the firm cited Tempus AI, Inc.’s (NASDAQ:TEM) ‘clouded visibility’ on data upside and a revision to its outlook for Ambry as the reason behind the adjustment.

As of the close of business on March 4, the stock is a Moderate Buy, with an average upside potential of 52.5%.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Magic Formula Stocks for 2026.

Disclosure: None. Follow Insider Monkey on Google News.